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emOBJECTIVES The purpose of this study was to compare outcomes (and the effect of sacubitril/valsartan) according to
etiology in the PARADIGM-HF (Prospective comparison of angiotensin-receptor-neprilysin inhibitor [ARNI] with angio-
tensin-converting-enzyme inhibitor [ACEI] to Determine Impact on Global Mortality and morbidity in Heart Failure) trial.
BACKGROUND Etiology of heart failure (HF) has changed over time in more developed countries and is also evolving in
non-Western societies. Outcomes may vary according to etiology, as may the effects of therapy.
METHODS We examined outcomes and the effect of sacubtril/valsartan according to investigator-reported etiology in
PARADIGM-HF. The outcomes analyzed were the primary composite of cardiovascular death or HF hospitalization, and
components, and death from any cause. Outcomes were adjusted for known prognostic variables including N terminal
pro-B type natriuretic peptide.
RESULTS Among the 8,399 patients randomized, 5,036 patients (60.0%) had an ischemic etiology. Among the 3,363
patients (40.0%) with a nonischemic etiology, 1,595 (19.0% of all patients; 47% of nonischemic patients) had idiopathic
dilated cardiomyopathy, 968 (11.5% of all patients; 28.8% of nonischemic patients) had a hypertensive cause, and 800
(9.5% of all patients, 23.8% of nonischemic patients) another cause (185 infective/viral, 158 alcoholic, 110 valvular, 66
diabetes, 30 drug-related, 14 peripartum–related, and 237 other). Whereas the unadjusted rates of all outcomes were
highest in patients with an ischemic etiology, the adjusted hazard ratios (HRs) were not different from patients in the 2
major nonischemic etiology categories; for example, for the primary outcome, compared with ischemic (HR: 1.00),
hypertensive 0.87 (95% confidence interval [CI]: 0.75 to 1.02), idiopathic 0.92 (95% CI: 0.82 to 1.04) and other 1.00
(95% CI: 0.85 to 1.17). The benefit of sacubitril/valsartan over enalapril was consistent across etiologic categories
(interaction for primary outcome; p ¼ 0.11).
CONCLUSIONS Just under one-half of patients in this global trial had nonischemic HF with reduced ejection fraction,
with idiopathic and hypertensive the most commonly ascribed etiologies. Adjusted outcomes were similar across etiologic
categories, as was the benefit of sacubitril/valsartan over enalapril. (Efficacy and Safety of LCZ696 Compared to Enalapril
on Morbidity and Mortality of Patients With Chronic Heart Failure; NCT01035255) (J Am Coll Cardiol HF 2019;7:457–65)
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ACEI = angiotensin-converting
enzyme inhibitor
AF = atrial fibrillation
CV = cardiovascular
EF = ejection fraction
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
LVEF = left ventricular ejection
fraction
and AstraZ
Celladon, C
Sanofi, Pas
Squibb, Ca
Genetics, C
from Astraz
personal fe
Relypsa, A
paid by No
principal i
PARADISE
aliskiren a
payments w
these trials
committee
sponsored
ported tha
Manuscript
Balmforth et al. J A C C : H E A R T F A I L U R E V O L . 7 , N O . 6 , 2 0 1 9
Etiology and Outcomes in PARADIGM-HF J U N E 2 0 1 9 : 4 5 7 – 6 5
458T he etiology of heart failure (HF) haschanged over time in more devel-oped countries and is also evolving
in less developed and other non-Western so-
cieties (1–9). In the first report from the Fra-
mingham Heart Study, initiated in 1949 and
published in 1971, hypertension was the
most common etiology in patients recruited
in the United States, although in that report
HF was not subclassified by ejection fraction
(EF) phenotype (1). More recently, in most
reports, coronary heart disease has become
the predominant cause of HF with reducedEF (HFrEF) (1–11). An epidemiologic transition has
also occurred in Eastern Europe, Asia, and Africa
from hypertension and rheumatic valvular disease
to coronary heart disease (1–11).SEE PAGE 466Etiology is important for a number of reasons.
First, outcome may vary according to etiology with
nonischemic causes purported to carry a better
prognosis than HF of ischemic origin (12,13). Second,
specific etiologies may be an indication for specific
therapies (e.g., bypass surgery for coronary artery
disease) (14). Third, and more controversially, it has
been suggested that the effectiveness of certain
treatments for HFrEF may be modified by etiology
(e.g., implantable cardiac defibrillator therapy in
nonischemic cardiomyopathy and cardiac resynchro-
nization therapy in ischemic compared with non-
ischemic HFrEF) (15,16).
To examine etiology in a contemporary and
globally representative sample of patients with
HFrEF, we examined investigator-reported cause
of HF in the PARADIGM-HF (Prospective Compari-
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[ACEI] to Determine Impact on Global Mortality and
Morbidity in Heart Failure) trial which enrolled 8399
patients in 47 countries on 6 continents (17–19). We
also examined outcomes according to etiology,
adjusting for a more extensive range of other prog-
nostic variables, including natriuretic peptides, than
in prior studies. Lastly, we also examined the effect
of the angiotensin-receptor-neprilysin inhibitor
sacubitril/valsartan compared with the ACEI enalap-
ril, according to etiology.
METHODS
PATIENTS AND PROCEDURES. The design and pri-
mary results of PARADIGM-HF have been reported (17–
19). Briefly, PARADIGM-HF was a randomized, double-
blind comparison of sacubitril/valsartan with enalapril
in patients with chronic HF and HFrEF. Eligibility
criteria at screening included New York Heart Associ-
ation (NYHA) functional class II to IV, left ventricular
ejection fraction (LVEF) #40 [changed to #35 by
amendment], and elevated natriuretic peptides.
Exclusion criteria at screening included symptomatic
hypotension or systolic blood pressure <100 mm Hg,
estimated glomerular filtration rate <30 ml/
min/1.73 m2, and potassium >5.2 mmol/l.
At trial entry, ongoing treatment with ACEI or
angiotensin receptor blocker (ARB) was stopped and
patients entered 2 sequential run-in periods, first
receiving enalapril 10 mg twice daily for 2 weeks
followed by sacubitril/valsartan for an additional 4
to 6 weeks, uptitrated from 49/51 mg to 97/103 mg
twice daily. Patients tolerating both drugs at these
target doses were randomly assigned to double-
blind therapy with sacubitril/valsartan or enalapril
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459The trial was approved by the ethics committees at
each participating institution and all patients pro-
vided written informed consent.
INVESTIGATOR-REPORTED ETIOLOGY. The etiology
of HF was collected by means of structured questions
on the trial case report form. Investigators were first
asked whether the primary etiology was ischemic or
nonischemic. If the answer nonischemic was checked,
investigators were then asked to specify from a
number of options (listed in the following order):
primary valvular (specify valve and surgery), alco-
holic, hypertensive, idiopathic, peripartum, infec-
tious cardiomyopathy, viral cardiomyopathy,
diabetic, drug induced (specify type of drug), and
“other” (please specify). For the purposes of this
analysis, patients were categorized as ischemic or
nonischemic, with nonischemic etiology further sub-
categorized into idiopathic, hypertensive and other,
because the numbers of cases in “other” were indi-
vidually too few to allow robust analysis.
OUTCOMES. The primary endpoint in PARADIGM-HF
was a composite of cardiovascular (CV) death or HF
hospitalization. In this study, we investigated the as-
sociation between etiology and the risk of the primary
outcome, each of its components, and all-cause mor-
tality. All endpoints were adjudicated by a clinical
endpoint committee in a blinded fashion. We also
compared the effects of the randomized treatment on
these outcomes, according to etiology, as
described below.
Stat i s t i ca l analyses . Baseline characteristics are
presented as frequencies and percentages for cate-
gorical variables and means with SD or medians with
interquartile range for continuous variables. Differ-
ences in baseline characteristics were tested using
chi-square test for categorical variables and analysis
of variance or Kruskal-Wallis test for continuous
variables.
Incidence rates for each outcome of interest are
presented per 100 person-years of follow-up. Event
rates in each etiologic category were estimated by the
Kaplan-Meier method and compared using the log-
rank test. Cox proportional hazards regression
models were used to compare hazard ratios (HRs)
with 95% confidence intervals according to etiology.
In multivariable models, the HR was adjusted for the
following baseline characteristics: age, sex, race, re-
gion, systolic blood pressure, heart rate, EF, NYHA
functional class, history of HF hospitalization, dura-
tion of HF, atrial fibrillation (AF), body mass index,
prior stroke, creatinine, randomized treatment
(sacubitril/valsartan or enalapril), and log N terminal
pro-B-type natriuretic peptide.Analyses were performed using Stata version 13
(Stata Corp., College Station, Texas) and SAS version
9.4 (SAS Institute Inc., Cary, North Carolina). All
p values are 2-sided, and a p < 0.05 was considered
significant.
RESULTS
Of the total 8,399 patients randomized, 5,036 patients
(60.0%) had an ischemic etiology and 3,363 patients
(40.0%) had a nonischemic etiology. Among those
with a nonischemic etiology, 1,595 patients (19.0% of
all patients; 47% of nonischemic patients) were re-
ported to have an idiopathic dilated cardiomyopathy,
968 (11.5% of all patients; 28.8% of nonischemic pa-
tients) a hypertensive cause and 800 (9.5% of all pa-
tients, 23.8% of nonischemic patients) another cause
(185 infective/viral, 158 alcoholic, 110 valvular, 66
diabetes, 30 drug-related, 14 peripartum related, and
237 “other”).
BASELINE CHARACTERISTICS. The clinical charac-
teristics of the patients categorized by etiology are
shown in Table 1. Patients with an ischemic (and hy-
pertensive) etiology were older than those in the other
nonischemic categories. Patients with an ischemic
etiology were also more likely to be male and Cauca-
sian. Nonischemic idiopathic patients were more
frequently female and Asian (and nonischemic hy-
pertensive patients were also more frequently female
and black and less often Asian) than ischemic patients.
Nonischemic patients were more often from Latin
American and Asia, compared with ischemic patients.
LVEF was slightly but significantly lower in pa-
tients with idiopathic dilated cardiomyopathy
compared to patients with an ischemic etiology and a
hypertensive cause; however, natriuretic peptide
concentrations did not differ meaningfully among the
various etiologic categories.
History of myocardial infarction was more frequent
in the ischemic group and hypertension and AF were
each more common in the hypertensive etiology
category. Conversely, history of diabetes was less
frequent in the idiopathic group.
Investigator-reported etiology seemed to vary by
geographic region. Ischemic etiology was most
frequent in Central/Eastern Europe (70%) and least
common in Latin America (43%) (Online Table 1).
Among the nonischemic etiologies, hypertensive eti-
ology was most common in Latin America (21% of all
cases of HFrEF) and least common in the Asia-Pacific
Region (6%), whereas idiopathic etiology was most
common in the Asia Pacific Region (28%) and least
common in Central/Eastern Europe and North
TABLE 1 Baseline Characteristics According to Investigator-Reported Heart Failure Etiology
Ischemic
(n ¼ 5,036)
Nonischemic (N ¼ 3,363)
p Value
Hypertensive
(n ¼ 968)
Idiopathic
(n ¼ 1,595)
Other
(n ¼ 800)
Age, yrs 65.7  10.2 64.7  11.5 60.0  12.3 58.3  12.6 <0.001
Female 969 (19.2) 283 (29.2) 373 (29.2) 207 (25.9) <0.001
Race or ethnic group
White 3,586 (71.2) 607 (62.7) 878 (55.1) 473 (59.1) <0.001
Black 110 (2.2) 117 (12.1) 97 (6.1) 104 (13.0)
Asian 891 (17.7) 89 (9.2) 416 (26.1) 113 (14.1)
Other 449 (8.9) 155 (16.0) 204 (12.8) 110 (13.8)
Region
North America 381 (7.6) 65 (6.7) 82 (5.1) 74 (9.3) <0.001
Latin America 617 (12.3) 301 (31.1) 308 (19.3) 207 (25.9)
Western Europe and other 1,188 (23.6) 231 (23.9) 384 (24.1) 248 (31.0)
Central Europe 1,987 (39.5) 282 (29.1) 399 (25.0) 158 (19.8)
Asia-Pacific 863 (17.1) 89 (9.19) 422 (26.46) 113 (14.12)
SBP, mm Hg 121.9  15.2 126.6  15.1 118.4  15.0 117.6  14.9 <0.001
HR, beats/min 71.6  11.8 74.3  12.3 73.1  11.8 73.1  13.3 <0.001
BMI 28.1  5.3 29.4  5.8 27.6  5.9 28.2  5.6 <0.001
Serum creatinine, mg/dl 1.15  0.3 1.10  0.3 1.08  0.3 1.10  0.3 <0.001
Clinical features of HF
EF, % 30  6.1 30.4  6.0 28.0  6.2 28.3  6.5 <0.001
BNP, pg/ml 254 (159–458) 242 (146–463) 251 (142–533) 257 (139–481)
NT-pro-BNP, pg/ml 1,543 (850–2,981) 1,793 (1,027–3,702) 1,682 (910–3,595) 1,791 (933–3,502)
NYHA functional class <0.001
I 201 (4.0) 53 (5.5) 82 (5.1) 53 (6.6)
II 3,426 (68.0) 686 (70.9) 1,210 (75.9) 597 (74.6)
III 1,359 (27.0) 220 (22.7) 295 (18.5) 144 (18.0)
IV 41 (0.8) 8 (0.8) 7 (0.4) 4 (0.5)
Missing data 9 (0.2) 1 (0.1) 1 (0.1) 2 (0.25)
Medical history
Hypertension 3,784 (75.1) 955 (98.66) 744 (48.5) 427 (53.4) <0.001
Diabetes 1,980 (39.3) 307 (31.7) 392 (24.6) 228 (28.5) <0.001
Atrial fibrillation 1,746 (34.7) 439 (45.4) 561 (35.2) 345 (43.1) <0.001
Hospitalization for HF 3,111 (61.8) 586 (60.5) 1,040 (65.2) 537 (67.1) 0.002
Myocardial infarction 3,537 (70.2) 40 (4.1) 31 (1.9) 26 (3.3) <0.001
Stroke 515 (10.2) 82 (8.5) 82 (5.1) 46 (5.8) <0.001
Pre-trial use of ACE inhibitor 3,964 (78.7) 695 (71.8) 1,227 (76.9) 646 (80.8) <0.001
Pre-trial use of ARB 1,089 (21.6) 277 (28.6) 371 (23.3) 155 (19.4) <0.001
Prior PCI 1,674 (33.2) 34 (3.5) 55 (3.5) 38 (4.8) <0.001
Prior CABG 1,274 (25.3) 7 (0.7) 8 (0.5) 14 (1.8) <0.001
Treatments at randomization
Diuretic 3,932 (78.1) 803 (83.0) 1,339 (84.0) 664 (83.0) <0.001
Digitalis 1,252 (24.9) 309 (31.9) 653 (40.9) 325 (40.6) <0.001
Beta-blocker 4,695 (93.2) 882 (91.1) 1,502 (94.2) 727 (91.50) 0.008
Mineralocorticoid antagonist 2,643 (52.5) 522 (53.9) 1,002 (62.8) 504 (63.0) <0.001
Statin 3,560 (70.7) 369 (38.1) 556 (34.9) 238 (29.8) <0.001
Antiplatelet 3,476 (69.0) 388 (40.1) 587 (36.8) 285 (35.6) <0.001
ICD 832 (16.5) 71 (7.33) 222 (13.9) 118 (14.8) <0.001
CRT 324 (6.4) 33 (3.4) 146 (9.2) 71 (8.9) <0.001
Values are mean  SD, n (%), or median (interquartile range).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; BNP ¼ B-type natriuretic peptide; CABG ¼ coronary artery bypass graft;
CRT ¼ cardiac resynchronization therapy; EF ¼ ejection fraction; HF ¼ heart failure; HR ¼ heart rate; ICD ¼ implantable cardioverter-defibrillator; NT-proBNP ¼ N terminal–
pro-B-type natriuretic peptide; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; SBP ¼ systolic blood pressure.
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TABLE 2 Event Rates and Risks of the Primary Composite Endpoint of CV Mortality or HF Hospitalization, CV Mortality, HF Hospitalization,
and All-Cause Mortality According to HF Etiology
N Events Crude Rate per 100 Patient-Years
Unadjusted HR
(95% CI)
Adjusted HR*
(95% CI) p Value
Primary composite outcome
Ischemic 5,036 1,272 12.31 (11.66–13.01) 1.00 (reference) 1.00 (reference)
Nonischemic
Hypertensive 968 211 10.41 (9.09–11.91) 0.85 (0.73–0.98) 0.87 (0.75–1.02) 0.082
Idiopathic 1,595 357 10.95 (9.87–12.15) 0.89 (0.79–1.00) 0.92 (0.82–1.04) 0.207
Other 800 191 11.96 (10.37–13.78) 0.97 (0.83–1.13) 1.00 (0.85–1.17) 0.973
CV mortality
Ischemic 5,036 789 7.07 (6.60–7.58) 1.00 (reference) 1.00 (reference)
Nonischemic
Hypertensive 968 127 5.86 (4.92–6.97) 0.83 (0.68–1.00) 0.87 (0.72–1.06) 0.168
Idiopathic 1,595 228 6.57 (5.77–7.48) 0.93 (0.80–1.07) 0.96 (0.82–1.12) 0.616
Other 800 107 6.16 (5.10–7.44) 0.87 (0.71–1.07) 0.94 (0.76–1.16) 0.581
HF hospitalization
Ischemic 5,036 725 7.02 (6.53–7.55) 1.00 (reference) 1.00 (reference)
Nonischemic
Hypertensive 968 122 6.02 (5.04–7.19) 0.86 (0.71–1.04) 0.91 (0.74–1.11) 0.343
Idiopathic 1,595 221 6.78 (5.94–7.73) 0.96 (0.83–1.12) 1.02 (0.87–1.20) 0.770
Other 800 127 7.95 (6.68–9.46) 1.13 (0.93–1.36) 1.13 (0.93–1.39) 0.205
All-cause mortality
Ischemic 5,036 982 8.79 (8.26–9.36) 1.00 (reference) 1.00 (reference)
Nonischemic
Hypertensive 968 163 7.51 (6.44–8.76) 0.85 (0.72–1.01) 0.89 (0.75–1.06) 0.186
Idiopathic 1,595 268 7.72 (6.85–8.71) 0.88 (0.77–1.01) 0.93 (0.81–1.08) 0.349
Other 800 133 7.66 (6.46–9.07) 0.87 (0.73–1.05) 0.95 (0.79–1.15) 0.623
*Adjusted for age, sex, race, region, systolic blood pressure, heart rate, ejection fraction, NYHA functional class, history of HF hospitalization, duration of HF, atrial fibrillation,
body mass index, prior stroke, creatinine, randomized treatment, and log NT-proBNP.
CI ¼ confidence interval; CV ¼ cardiovascular; other abbreviations as in Table 1.
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461America (both 14%). However, because the numbers in
some of these subgroups were small, these analyses
may not be robust, and the apparent variation re-
ported requires further investigation in other
datasets.
Treatment at baseline varied by etiology with
digoxin use much more common in idiopathic pa-
tients (40.9%) compared to those with an ischemic
etiology (24.9%).
Statin and antiplatelet therapy was used much
more commonly in those with an ischemic etiology
compared to all other etiologic categories.
OUTCOMES ACCORDING TO ETIOLOGY. The rate of
the primary composite outcome, its components and
all-cause mortality are shown in Table 2 and Figure 1.
Although, the rate of all of these events was highest in
patients with an ischemic etiology, the adjusted HR
was not different from patients in the 2 major non-
ischemic etiology categories (idiopathic and hyper-
tensive). Repeating the analysis using any of history
of myocardial infarction, percutaneous coronary
intervention, coronary artery bypass grafting, unsta-
ble angina, or angina to define the ischemic subgroup,instead of investigator-reported ischemic etiology,
gave almost identical results (Online Table 2).
EFFECT OF SACUBITRIL/VALSARTAN ACCORDING
TO ETIOLOGY. The effect of sacubitril/valsartan,
compared to enalapril, on the primary composite
endpoint and CV death is shown in the Central
Illustration. The benefit of sacubitril/valsartan was
consistent across the etiologic categories (interaction
p value for primary endpoint ¼ 0.11; for CV
death ¼ 0.55).
DISCUSSION
In the largest and most globally representative trial to
date in patients with HFrEF, we found that the most
common etiology was ischemic heart disease (in 60%
of participants), although this varied with sex, race,
and geographic region. Gheorghiade et al. (20) re-
ported in a review of 24 trials published between 1986
and 2005 that 62% of patients had an investigator-
reported ischemic etiology and this coronary disease
and in more recent trials the proportion has varied
between 65% and 70% in studies with a high
FIGURE 1 Cumulative Incidence of Outcome According to Etiology (Ischemic, Idiopathic, Hypertensive, and Other)
(A) Cumulative incidence of primary composite outcome, (B) cardiovascular mortality, (C) heart failure hospitalization, and (D) all-cause mortality according to etiology
(ischemic, idiopathic, hypertensive, and other).
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462proportion of European patients (especially from
Central/Eastern Europe) to 56% in another large
global trial with significant numbers of patients from
Asia and Latin America (19–23). Of the nonischemic
etiologies reported, by far the largest category was
idiopathic (47% of nonischemic cases) and another
29% of cases were ascribed a hypertensive etiology.
Few prior studies have subcategorized etiology
beyond ischemic and nonischemic. Felker et al. (24)
studied 1,230 patients who underwent endomyo-
cardial biopsy between December 1982 and December
1997 at Johns Hopkins Hospital, as part of an evalu-
ation for HF due to unexplained cardiomyopathy. In
that highly selected cohort, 616 patients were diag-
nosed with an idiopathic cardiomyopathy (24) and
other etiologies were identified in much smaller
number of patients including myocarditis (n ¼ 111),HIV infection (n ¼ 45), hypertension (n ¼ 49), peri-
partum cardiomyopathy (n ¼ 51), infiltrative
myocardial disease (n ¼ 59), connective tissue disease
(n ¼ 39), substance abuse (n ¼ 37), doxorubicin ther-
apy (n ¼ 15), and other (n ¼ 117); in addition, 91 pa-
tients had (unexpected) ischemic heart disease. In a
more representative study, Pecini et al. (25) examined
data from 3,078 hospitalized patients screened be-
tween 2001 and 2002 for inclusion in a clinical trial in
Denmark. Overall, 1,924 (63%) of these patients had
an LVEF <45%. Six major etiologic groups were
identified by investigators: ischemic heart disease
(n ¼ 925; 48.1%), idiopathic dilated cardiomyopathy
(n ¼ 223; 11.6%), hypertension (n ¼ 204; 10.6%),
valvular heart disease (n ¼ 165; 8.6%), other (n ¼ 183;
9.5%), and unknown/mixed (n ¼ 224; 11.6%). Our
findings are broadly in keeping with these Danish
CENTRAL ILLUSTRATION Effect of Sacubitril/Valsartan According to Etiology of Heart Failure
A
All patients
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Effect of randomized therapy with sacubitril/valsartan (sac/val) or enalapril on the primary composite outcome (A), or cardiovascular
mortality (B) according to etiology (ischemic, idiopathic, hypertensive, and other). There was no significant treatment by etiology inter-
action. CI ¼ confidence interval; HR ¼ hazard ratio.
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463data, although an ischemic etiology was more com-
mon, overall, and valvular etiology less frequent, in
participants in PARADIGM-HF.
In keeping with prior reports, patients in
PARADIGM-HF with an ischemic etiology had a
higher crude incidence of adverse outcomes
(12,13,25). However, in contrast to previous findings,
when adjusted for other prognostic variables,
including we believe for the first time natriuretic
peptides, outcomes in PARADIGM-HF did not
differ by etiology (at least for the 3 largest
categoriesdischemic, idiopathic, and hypertensive).
In the 2 earlier studies mentioned above, themultivariable models used adjusted for few variables
and did not include natriuretic peptides in either
case. Moreover, evidence-based life-saving therapies
were not reported (Felker et al. [24]) or underused
(Pecini et al. [25]) in the aforementioned studies,
which were conducted before or at the beginning of
the beta-blocker era in management of HFrEF.
Consequently, it would appear that in contemporary
practice, mortality and morbidity are broadly similar
across the most common HFrEF etiologies when
other prognostic variables are adjusted for. We
cannot be certain whether this is also true for the
less common etiologies and it remains possible that
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Although globally an ischemic etiology is the most
commonly reported cause of HFrEF, approximately
40% of cases have a nonischemic etiology. How
outcomes vary according to etiology in contemporary
cohorts and whether etiology modifies response to
therapy in HFrEF is of interest. Although patients with
an investigator-reported ischemic etiology had worse
outcomes than those with a nonischemic etiology,
neither the unadjusted nor adjusted risk was signifi-
cantly different between these 2 groups. Outcomes
did not differ, either, between the 2 major nonische-
mic subgroups; those being hypertensive and idio-
pathic etiology. The benefit of sacubitril/valsartan,
compared with enalapril, was consistent across etio-
logic category.
TRANSLATIONAL OUTLOOK: Although there may
be some misclassification of cause of HF in studies
using investigator-reported etiology, the present
analysis suggests no major difference in outcomes
according to etiology in patients treated with
contemporary therapies and that etiology does not
modify the response to sacubitril/valsartan. Once
HFrEF is established, left ventricular systolic
dysfunction and the resultant maladaptive compen-
satory responses, rather than underlying cause, may
become the main determinants of outcome in pa-
tients. Treatments targeted at these pathophysiologic
abnormalities may also be equally effective, irre-
spective of etiology.
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464among patients labelled as having an idiopathic
dilated cardiomyopathy there may be subgroups of
patients defined by genetic or other variables that
fare better or worse than the rest.
In a developing era of precision medicine, more
detailed phenotyping (and genotyping) of patients
has been advocated to target treatments to patients
more likely to benefit (26). Etiology is one aspect of
phenotyping which may help determine choice of
therapy. Surgical revascularization improves out-
comes in selected patients with coronary artery
disease and implantable cardioverter therapy may
be less effective in patients with nonischemic
dilated cardiomyopathy (14,15). Other biomarkers
and comorbidities may identify patients more or
less likely to benefit from specific drug therapies;
for example, ivabradine is effective in patients with
a higher heart rate and beta-blockers may be less
effective in patients in AF (23,27). In the acute
setting, the efficacy and safety of intravenous mil-
rinone appeared to be modified by etiology— with
worse treatment-related outcomes in patients with
an ischemic etiology and better outcomes in non-
ischemic patients (28). On the other hand, other
treatments such as ACEIs, ARBs and mineralocorti-
coid receptor antagonists appear equally effective
across all phenotypic subgroups examined. We have
previously reported that sacubitril/valsartan is
similarly effective in subgroups defined by comor-
bidity and biomarkers (blood pressure, heart rate,
natriuretic peptides, and estimated glomerular
filtration rate) (19,29–32). Here we show a benefit
irrespective of etiology (at least across the major
etiologic categories identified by investigators).
STUDY LIMITATIONS. As with any study of this type,
there are limitations. The analyses conducted were
not pre-planned and the patients analyzed were
those enrolled on a clinical trial rather than an un-
selected community cohort. Etiology was
investigator-reported and no specific instructions
were provided as to how to identify etiology. Pa-
tients may not have been exhaustively investigated
for specific causes of HF, and some degree of etio-
logic misclassification will have occurred. The diffi-
culties of ascribing a coronary etiology, even with
angiography, have been discussed (33). It was not
possible to examine outcomes in nonischemic etio-
logic categories other than the idiopathic and hy-
pertensive groups because of small numbers.
Similarly, it would have been of interest to study
subcategories of CV mortality according to etiology,
but this was also impossible because of the small
numbers of events.CONCLUSIONS
In summary, in PARADIGM-HF, the most common
HFrEF etiology was ischemic heart disease (in 60% of
participants). Of the nonischemic etiologies reported,
the largest category was idiopathic (47% of non-
ischemic cases) and another 29% of patients were
ascribed a hypertensive etiology. When adjusted for
other prognostic variables, including natriuretic
peptides, outcomes were similar across etiologic cat-
egories. The benefit of sacubitril/valsartan over ena-
lapril was not modified by etiology.
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